Compositions and methods for stabilizing susceptible compounds
Abstract
Methods for increasing the stability of, or protecting, labile components such as ethanolamine, growth factors, vitamins, etc., in compositions such as a cell culture medium. Stability of the labile compound is increased either, by derivatization of the labile compound with chemicals, or by sequestering the labile compound. Sequestering can be done either by encapsulation within a microcapsule, or by the use of sequestering agents. Encapsulation includes the encapsulation of dendrimers complexes of susceptible compounds within the microcapsule, thereby providing the controlled release of the susceptible compound that was protected. These methods may improve and extend storage conditions of compositions comprising the labile compounds, improve shipping and handling of compositions comprising the labile compounds, such as dry media formulations, at room temperature rather than at lower temperatures thereby decreasing shipping costs. Stabilization of labile compounds in compositions such as dry format media can be viewed as a contribution to green technology.

Term
5.4 yearsto projected expiry
Projected expiry 7 February 2032, counted from filing; an application has no term until it is granted.
- Priority
- Filed
- Published
- Today
- Projected expiry
1 sheet
Sheet 1
Every citation, both waysCites: the store holds 4 of 5
| Document | Relation | Office | Category | Cited during | Relevant claims |
|---|---|---|---|---|---|
| EP1702675A1 | Cites | European Patent Office (EPO) | X | Search report | 1-7,14,15 |
| WO2009042945A1 | Cites | World Intellectual Property Organization (WIPO) | X | Search report | 4,5,7 |
| WO2013096858A1 | Cites | World Intellectual Property Organization (WIPO) | E | Search report | 1-15 |
| WO9856426A1 | Cites | World Intellectual Property Organization (WIPO) | X | Search report | 1,3-7,14,15 |
| ALPERT ET AL: "Hydrophilic-interaction chromatography for the separation of peptides, nucleic acids and other polar compounds", JOURNAL OF CHROMATOGRAPHY, vol. 499, 19 January 1990 (1990-01-19), pages 177 - 196, XP026484536, ISSN: 0021-9673, DOI: 10.1016/S0021-9673(00)96972-3 | Non-patent | – | – | Search report | – |
| CHURMS S C: "Recent progress in carbohydrate separation by high-performance liquid chromatography based on hydrophilic interaction", JOURNAL OF CHROMATOGRAPHY, vol. 720, no. 1, 12 January 1996 (1996-01-12), pages 75 - 91, XP004038350, ISSN: 0021-9673, DOI: 10.1016/0021-9673(95)00306-1 | Non-patent | – | – | Search report | – |
| ANDRÉA MARA RIGHETTO ET AL: "Vitamin C stability in encapsulated green West Indian cherry juice and in encapsulated synthetic ascorbic acid", JOURNAL OF THE SCIENCE OF FOOD AND AGRICULTURE, vol. 86, no. 8, 1 June 2006 (2006-06-01), pages 1202 - 1208, XP055092721, ISSN: 0022-5142, DOI: 10.1002/jsfa.2469 | Non-patent | – | – | Search report | – |
| DUSICA MAYSINGER ET AL: "Microencapsulated Ciliary Neurotrophic Factor: Physical Properties and Biological Activities", EXPERIMENTAL NEUROLOGY, vol. 138, no. 2, 1 April 1996 (1996-04-01), pages 177 - 188, XP055132514, ISSN: 0014-4886, DOI: 10.1006/exnr.1996.0056 | Non-patent | – | – | Search report | – |
| SIDERATOU Z ET AL: "Arginine end-functionalized poly(l-lysine) dendrigrafts for the stabilization and controlled release of insulin", JOURNAL OF COLLOID AND INTERFACE SCIENCE, vol. 351, no. 2, 4 August 2010 (2010-08-04), pages 433 - 441, XP027331912, ISSN: 0021-9797 | Non-patent | – | – | Search report | – |
| DANIEL E. KEHOE ET AL: "Scalable Stirred-Suspension Bioreactor Culture of Human Pluripotent Stem Cells", TISSUE ENGINEERING: PART A, vol. 16, no. 2, 1 January 2010 (2010-01-01), pages 405 - 421, XP055054581 | Non-patent | – | – | Search report | – |
| BURGAIN J ET AL: "Encapsulation of probiotic living cells: From laboratory scale to industrial applications", JOURNAL OF FOOD ENGINEERING, vol. 104, no. 4, 5 January 2011 (2011-01-05), pages 467 - 483, XP028173566, ISSN: 0260-8774, DOI: 10.1016/J.JFOODENG.2010.12.031 | Non-patent | – | – | Search report | – |
| ANNAN ET AL: "Encapsulation in alginate-coated gelatin microspheres improves survival of the probiotic Bifidobacterium adolescentis 15703T during exposure to simulated gastro-intestinal conditions", FOOD RESEARCH INTERNATIONAL, vol. 41, no. 2, 17 November 2007 (2007-11-17), pages 184 - 193, XP022475730, ISSN: 0963-9969, DOI: 10.1016/J.FOODRES.2007.11.001 | Non-patent | – | – | Search report | – |
| GIBBS B F ET AL: "ENCAPSULATION IN THE FOOD INDUSTRY: A REVIEW", INTERNATIONAL JOURNAL OF FOOD SCIENCES AND NUTRITION, vol. 50, no. 3, 1999, pages 213 - 224, XP009013399, ISSN: 0963-7486, DOI: 10.1080/096374899101256 | Non-patent | – | – | Search report | – |
| WASSANA WIJAGKANALAN ET AL: "Designing Dendrimers for Drug Delivery and Imaging: Pharmacokinetic Considerations", PHARMACEUTICAL RESEARCH, vol. 28, no. 7, 23 December 2010 (2010-12-23), pages 1500 - 1519, XP019912545, ISSN: 1573-904X, DOI: 10.1007/S11095-010-0339-8 | Non-patent | – | – | Search report | – |
| MURAKAMI H ET AL: "Growth of hybridoma cells in serum-free medium: ethanolamine is an essential component.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 79, no. 4, February 1982 (1982-02-01), pages 1158 - 1162, XP002674921, ISSN: 0027-8424 | Non-patent | – | – | Search report | – |
| KANO-SUEOKA T ET AL: "Effects of phosphoethanolamine and ethanolamine on growth of mammary carcinoma cells in culture", EXPERIMENTAL CELL RESEARCH, vol. 136, no. 1, 1 November 1981 (1981-11-01), pages 137 - 145, XP024858739, ISSN: 0014-4827 | Non-patent | – | – | Search report | – |
| MAZIERE C ET AL: "Effect of manipulation of phospholipid polar head group on low density lipoprotein metabolism in human cultured fibroblasts", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 137, no. 1, 29 May 1986 (1986-05-29), pages 43 - 49, XP024835811, ISSN: 0006-291X | Non-patent | – | – | Search report | – |
| LU T-R ET AL: "Comparison of the biological stability of liposome-encapsulated nerve growth factor at different depot stages", CHINESE JOURNAL OF CLINICAL REHABILITATION, vol. 9, no. 29, 7 August 2005 (2005-08-07), pages 214 - 216, XP009169672, ISSN: 1671-5926 | Non-patent | – | – | Search report | – |
| CLELAND J L ET AL: "STABLE FORMULATIONS OF RECOMBINANT HUMAN GROWTH HORMONE AND INTERFERON-GAMMA FOR MICROENCAPSULATION IN BIODEGRADABLE MICROSPHERES", PHARMACEUTICAL RESEARCH, vol. 13, no. 10, 1 January 1996 (1996-01-01), pages 1464 - 1475, XP001084606, ISSN: 0724-8741, DOI: 10.1023/A:1016063109373 | Non-patent | – | – | Search report | – |
24 members in 6 offices
Priority claims7
| Document | Office | Kind | Date |
|---|---|---|---|
| 201161440237 | United States of America | P | |
| 201161440237P | United States of America | – | |
| 12706364 | European Patent Office (EPO) | A | |
| 127063642 | – | – | – |
| 201161440237P | – | – | – |
| EP20120706364 | – | – | – |
| US201161440237P | – | – | – |
Members24
| Document | Office | Kind | |
|---|---|---|---|
| WO2012109279A2 | World Intellectual Property Organization (WIPO) | A2 | |
| WO2012109279A3 | World Intellectual Property Organization (WIPO) | A3 | |
| CN103348000A | China | A | |
| US2013316004A1 | United States of America | A1 | |
| EP2673357A2 | European Patent Office (EPO) | A2 | |
| JP2014509843A | Japan | A | |
| KR20140057192A | Republic of Korea | A | |
| EP2778221A2 | European Patent Office (EPO) | A2 | |
| EP2778221A3This record | European Patent Office (EPO) | A3 | |
| EP3156480A2 | European Patent Office (EPO) | A2 | |
| JP6143679B2 | Japan | B2 | |
| EP3156480A3 | European Patent Office (EPO) | A3 | |
| EP2778221B1 | European Patent Office (EPO) | B1 | |
| CN103348000B | China | B | |
| JP2017169577A | Japan | A | |
| CN107699540A | China | A | |
| KR102007997B1 | Republic of Korea | B1 | |
| KR20190092629A | Republic of Korea | A | |
| EP3156480B1 | European Patent Office (EPO) | B1 | |
| JP6680721B2 | Japan | B2 | |
| US10669522B2 | United States of America | B2 | |
| US2020190465A1 | United States of America | A1 | |
| US11028361B2 | United States of America | B2 | |
| US2021269767A1 | United States of America | A1 |
73 legal events, as 10 offices reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | Office | |
|---|---|---|---|
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Opt-out of the competence of the unified patent court (upc) registeredP01 | P01 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed because of non-payment of the annual feeLapsedMM | MM | BE | |
| Patent lapsedLapsedMM4A | MM4A | IE | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| No opposition filedOpposition26N | 26N | EP | |
| No opposition filed within time limitOppositionORIGINAL CODE: 0009261PLBE | PLBE | EP | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: NO OPPOSITION FILED WITHIN TIME LIMITSTAA | STAA | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| No opposition filed against granted patent, or epo opposition proceedings concluded without decisionGrantedR097 | R097 | DE | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Fee paymentPLFP | PLFP | FR | |
| Deletion acc. to par. 5 (withdrawal of the translation of the ep patent)MK05 | MK05 | AT | |
| Invalidated european patentMG4D | MG4D | LT | |
| New agentNV | NV | CH | |
| Dpma publication of mentioned ep patent grantGrantedR096 | R096 | DE | |
| Translation for ep filed (entry of ep into country)FP | FP | NL | |
| European patents granted designating irelandGrantedFG4D | FG4D | IE | |
| Reference to at number (ep patent validated in austria)REF | REF | AT | |
| European patent takes effect as a national patent in ch/liEP | EP | CH | |
| Divisional application: reference to earlier applicationAC | AC | EP | |
| Designated contracting statesAK | AK | EP | |
| European patent grantedGrantedFG4D | FG4D | GB | |
| (expected) grantORIGINAL CODE: 0009210GRAA | GRAA | EP | |
| Grant fee paidORIGINAL CODE: EPIDOSNIGR3GRAS | GRAS | EP | |
| Intention to grant announcedINTG | INTG | EP | |
| Despatch of communication of intention to grant a patentORIGINAL CODE: EPIDOSNIGR1GRAP | GRAP | EP | |
| Party data changed (applicant data changed or rights of an application transferred)RAP1 | RAP1 | EP | |
| First examination report despatched17Q | 17Q | EP | |
| Request for examination filed (corrected)R17P | R17P | EP | |
| Designated contracting states (corrected)RBV | RBV | EP | |
| Designated contracting statesAK | AK | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Search report despatchedORIGINAL CODE: 0009013PUAL | PUAL | EP | |
| Request for examination filed17P | 17P | EP | |
| Divisional application: reference to earlier applicationAC | AC | EP | |
| Designated contracting statesAK | AK | EP | |
| Public reference made under article 153(3) epc to a published international application that has entered the european phaseORIGINAL CODE: 0009012PUAI | PUAI | EP |
Numbers
- Publication
- 2778221
- Publication, DOCDB
- 2778221
- Publication, EPODOC
- EP2778221
- Application
- 141611400
- Application, DOCDB
- 14161140
- Application, EPODOC
- EP20140161140
Titles3
- German
- Zusammensetzungen und Verfahren zur Stabilisierung von empfindlichen Verbindungen
- English
- Compositions and methods for stabilizing susceptible compounds
- French
- Compositions et procédés de stabilisation de composés sensibles
Classification
- CPC, 3
- C12N5/0018
- C12N2500/34
- C12N2500/46
- IPC, 1
- C12N5 00
Designated states1
- Contracting states, 1
- Türkiye